232 related articles for article (PubMed ID: 38557676)
1. Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology.
Arulraj T; Wang H; Ippolito A; Zhang S; Fertig EJ; Popel AS
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38557676
[TBL] [Abstract][Full Text] [Related]
2. From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy.
Lemaire V; Bassen D; Reed M; Song R; Khalili S; Lien YTK; Huang L; Singh AP; Stamatelos S; Bottino D; Hua F
Clin Pharmacol Ther; 2023 May; 113(5):963-972. PubMed ID: 36282521
[TBL] [Abstract][Full Text] [Related]
3. Emulation of Quantitative Systems Pharmacology models to accelerate virtual population inference in immuno-oncology.
Pawłowski T; Bokota G; Lazarou G; Kierzek AM; Sroka J
Methods; 2024 Mar; 223():118-126. PubMed ID: 38246229
[TBL] [Abstract][Full Text] [Related]
4. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
Sové RJ; Jafarnejad M; Zhao C; Wang H; Ma H; Popel AS
CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):484-497. PubMed ID: 32618119
[TBL] [Abstract][Full Text] [Related]
5. Multi-Omics Profiling of the Tumor Microenvironment.
Van Oekelen O; Laganà A
Adv Exp Med Biol; 2022; 1361():283-326. PubMed ID: 35230695
[TBL] [Abstract][Full Text] [Related]
6. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.
Chelliah V; Lazarou G; Bhatnagar S; Gibbs JP; Nijsen M; Ray A; Stoll B; Thompson RA; Gulati A; Soukharev S; Yamada A; Weddell J; Sayama H; Oishi M; Wittemer-Rump S; Patel C; Niederalt C; Burghaus R; Scheerans C; Lippert J; Kabilan S; Kareva I; Belousova N; Rolfe A; Zutshi A; Chenel M; Venezia F; Fouliard S; Oberwittler H; Scholer-Dahirel A; Lelievre H; Bottino D; Collins SC; Nguyen HQ; Wang H; Yoneyama T; Zhu AZX; van der Graaf PH; Kierzek AM
Clin Pharmacol Ther; 2021 Mar; 109(3):605-618. PubMed ID: 32686076
[TBL] [Abstract][Full Text] [Related]
8. Virtual Populations for Quantitative Systems Pharmacology Models.
Cheng Y; Straube R; Alnaif AE; Huang L; Leil TA; Schmidt BJ
Methods Mol Biol; 2022; 2486():129-179. PubMed ID: 35437722
[TBL] [Abstract][Full Text] [Related]
9. Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model.
Ruiz-Martinez A; Gong C; Wang H; Sové RJ; Mi H; Kimko H; Popel AS
PLoS Comput Biol; 2022 Jul; 18(7):e1010254. PubMed ID: 35867773
[TBL] [Abstract][Full Text] [Related]
10. Recent applications of quantitative systems pharmacology and machine learning models across diseases.
Aghamiri SS; Amin R; Helikar T
J Pharmacokinet Pharmacodyn; 2022 Feb; 49(1):19-37. PubMed ID: 34671863
[TBL] [Abstract][Full Text] [Related]
11. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
Fleisher B; Brown AN; Ait-Oudhia S
Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
[TBL] [Abstract][Full Text] [Related]
12. IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures.
Zeng D; Ye Z; Shen R; Yu G; Wu J; Xiong Y; Zhou R; Qiu W; Huang N; Sun L; Li X; Bin J; Liao Y; Shi M; Liao W
Front Immunol; 2021; 12():687975. PubMed ID: 34276676
[TBL] [Abstract][Full Text] [Related]
13. Physiological Indirect Response Model to Omics-Powered Quantitative Systems Pharmacology Model.
Uatay A; Gall L; Irons L; Tewari SG; Zhu XS; Gibbs M; Kimko H
J Pharm Sci; 2024 Jan; 113(1):11-21. PubMed ID: 37898164
[TBL] [Abstract][Full Text] [Related]
14. Integration of Omics Data Sources to Inform Mechanistic Modeling of Immune-Oncology Therapies: A Tutorial for Clinical Pharmacologists.
Lazarou G; Chelliah V; Small BG; Walker M; van der Graaf PH; Kierzek AM
Clin Pharmacol Ther; 2020 Apr; 107(4):858-870. PubMed ID: 31955413
[TBL] [Abstract][Full Text] [Related]
15. Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.
Cheng L; Qiu Y; Schmidt BJ; Wei GW
J Pharmacokinet Pharmacodyn; 2022 Feb; 49(1):39-50. PubMed ID: 34637069
[TBL] [Abstract][Full Text] [Related]
16. Dynamical systems analysis as an additional tool to inform treatment outcomes: The case study of a quantitative systems pharmacology model of immuno-oncology.
Balti A; Zugaj D; Fenneteau F; Tremblay PO; Nekka F
Chaos; 2021 Feb; 31(2):023124. PubMed ID: 33653032
[TBL] [Abstract][Full Text] [Related]
17. A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy.
Gong C; Ruiz-Martinez A; Kimko H; Popel AS
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359653
[TBL] [Abstract][Full Text] [Related]
18. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy.
Lee JY; Kannan B; Lim BY; Li Z; Lim AH; Loh JW; Ko TK; Ng CC; Chan JY
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887186
[TBL] [Abstract][Full Text] [Related]
19. Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition.
Wang H; Arulraj T; Kimko H; Popel AS
NPJ Precis Oncol; 2023 Jun; 7(1):55. PubMed ID: 37291190
[TBL] [Abstract][Full Text] [Related]
20. Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition.
Wang H; Arulraj T; Kimko H; Popel AS
bioRxiv; 2023 Apr; ():. PubMed ID: 37162938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
